clinical trial · NCT03123406
Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT
Kyowa Kirin China Pharmaceutical Co., Ltd.·phase4·completed·n = 750
Hyperparathyroidism; Secondary, RenalCinacalcet HCl
brief summary
1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2. To explore the impact of Cinacalcet HCL using on the combined use of drugs; 3. To explore the difference of patients who continued or discontinued Cinacalcet HCL in real-world period from 33rd to 52nd week.
started
Apr 19, 2017
primary completion
Apr 20, 2019
completion
Sep 6, 2019
last updated
Apr 29, 2024
official title
A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol